深圳博雅感知药业

Boya Perception Pharmaceutical is a clinical-stage biotechnology company based in Shenzhen, China, focused on developing innovative small molecule therapies for sensory-related conditions, including pain, anesthesia, and pruritus. Founded in 2021 by industry veteran Dr. Tang Jidong, the company targets the perception system to address significant unmet needs in the central and peripheral nervous systems. Its lead candidate, BY001, is a novel GABA-A receptor modulator currently in Phase 2 clinical trials for anesthesia and sedation. The company's pipeline also includes BY002, a selective Nav1.8 inhibitor for pain management, aiming to provide non-opioid alternatives for acute and chronic pain. Boya Perception leverages its proprietary platform to discover highly selective molecules with improved safety profiles compared to existing standards of care.